Background Other than glycemic control, there are no treatments for diabetic neuropathy.
Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk …

Background This study was undertaken to determine whether use of the direct renin inhibitor
aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and …

Objectives : This study sought to determine whether ethnic differences in diabetes,
dyslipidemia, and ectopic fat deposition account for ethnic differences in incident cardiovascular …

Background Retinopathy commonly occurs in people with type 1 diabetes. Strict glycaemic
control can decrease development and progression of retinopathy only partially. Blood …

Blood pressure is a heritable trait 1 influenced by several biological pathways and responsive
to environmental stimuli. Over one billion people worldwide have hypertension (≥140 mm …

Background— High-throughput profiling of circulating metabolites may improve cardiovascular
risk prediction over established risk factors. Methods and Results— We applied …

Background Renal disease in people with insulin-dependent diabetes (IDDM) continues to
pose a major health threat. Inhibitors of angiotensin-converting enzyme (ACE) slow the …

Background Results of previous studies suggest that renin-angiotensin system blockers
might reduce the burden of diabetic retinopathy. We therefore designed the DIabetic …

Background Diabetic retinopathy remains a leading cause of visual loss in people of
working age. We examined whether candesartan treatment could slow the progression and, …

Background: The associations of body mass index (BMI) and chronic disease may differ
between Indo-Asian and Western populations. We used Indo-Asian-specific definitions of …